Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Recruiting 7Not yet recruiting 6Completed 6Active not recruiting 3Unknown 1Terminated 1Approved for marketing 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Small Cell Lung Carcinoma 3Sarcoma 1Platinum-Resistant Lung Small Cell Carcinoma 1Neoplasms 1Leiomyosarcoma 1

Interventions

Carboplatin 15durvalumab 14Etoposide 14pembrolizumab 9atezolizumab 9Cisplatin 9Topotecan 8Nivolumab 7Specimen Handling 6olaparib 4berzosertib 4Temozolomide 4Magnetic Resonance Spectroscopy 4AMG 757 4tremelimumab 3Radiotherapy 3Radiosurgery 3PM 01183 3Ipilimumab 3Docetaxel 3Biopsy 3niraparib 2lenvatinib 2cabozantinib 2Platinum 2Irinotecan 2Fulvestrant 2veliparib 1tislelizumab 1tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Small Cell Lung Carcinoma × PM 01183 × Clear all
NCT04802174 2026-03-17

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
37 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT05091567 2026-03-10

IMforte

Hoffmann-La Roche

Phase 3 Active not recruiting
660 enrolled 23 charts 1 FDA
Thoracic

Small Cell Lung Carcinoma

NCT05740566 2026-01-05

DeLLphi-304

Amgen

Phase 3 Active not recruiting
509 enrolled 11 charts 1 FDA
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡